Walt Disney Co vs ResMed Inc. — how do they compare? Walt Disney Co trades at $103.22 (market cap $178.76B), while ResMed Inc. trades at $220.4 (market cap $32.61B). The key difference: Walt Disney Co is far larger — about 5.5× ResMed Inc.'s market cap, and Walt Disney Co pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DIS | RMD | |
|---|---|---|
Market Cap | $178.76B | $32.61B |
Volume | 7,546,013 | — |
Sector | Media | Health |
52-Week High | $118.86 | $293.73 |
52-Week Low | $92.40 | $182.82 |
Enterprise Value | $219.62B | $31.97B |
Dividend Yield | 1.45% | 1.17% |
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $103.51, down 1.32% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with four consecutive quarterly earnings beats, revenue growth to $94.43B in 2025, and improving profit margins. Recent news highlights advertising opportunities from major events and ongoing FCC regulatory challenges.
Outlook remains positive with analyst consensus target of $126 representing 22% upside potential. Key opportunities include streaming growth and theme park investments, while risks involve regulatory disputes and box office performance variability. Wall Street maintains strong buy sentiment with 62.5% of analysts recommending purchase.
No Aura AI signal available yet.
Trailing returns across standard periods
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →